RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

MassVentures is a Massachusetts-based venture capital firm established in 1978 as a quasi-public entity to support seed and early-stage startups in the Commonwealth's innovation economy. It funds high-growth ventures from concept to commercialization and focuses on deep tech areas such as quantum computing, clean energy, AI, and biotech, alongside information technology, healthcare, cybersecurity, e-commerce, mobile, manufacturing, and robotics. The organization is governed by an independent board and backed by experienced investment professionals, and it provides funding, mentorship, strategic guidance, and non-dilutive grants through programs including MV Capital, MV Accelerate, and MV Spinouts, often in collaboration with academic institutions. MassVentures has funded more than 190 companies and has played a key role in expanding Massachusetts' innovation ecosystem by building inclusive teams and connecting founders with capital and expertise.

General Catalyst is a venture capital firm that funds early-stage and growth companies across sectors including consumer, enterprise software, fintech, crypto, and healthcare. Based in San Francisco with offices in Cambridge, Massachusetts and other locations, it provides capital and strategic guidance to help entrepreneurs build scalable, durable businesses. The firm emphasizes the use of technology, including artificial intelligence, to accelerate growth and drive meaningful impact. General Catalyst partners with management teams to support product development, go-to-market strategies, and organizational growth, aiming to back companies with potential for wide adoption and long-term value creation, rather than focusing solely on near-term exits.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

Flagship Pioneering is a Cambridge, Massachusetts-based venture builder that conceives, creates, resources, and scales first-in-category companies in health, biotechnology, and sustainability. It turns early scientific breakthroughs into durable platforms and enterprises by combining scientific discovery with entrepreneurial leadership and capital management, pursuing transformative outcomes through an evolutionary approach. With more than 25 years of experience, Flagship builds ecosystems that connect science, startups, and collaboration across partners. Notable portfolio companies include Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, Lila Sciences, and Serif Biomedicines, reflecting a focus on pioneering medicines, intelligence, and preemptive health. The firm collaborates with major partners such as Genentech, Pfizer, GSK, Novo Nordisk, and Montai Therapeutics and engages in technology partnerships like AWS to accelerate discovery. Flagship emphasizes global health impact and disruptive science, fostering programs and opportunities through initiatives such as the Flagship Fellowship.

Founder Collective is a seed- and pre-seed-focused venture capital firm headquartered in Cambridge, Massachusetts, with offices in New York City and Boston. It backs early-stage technology startups across the United States with a founder-aligned, long-term approach that emphasizes capital efficiency and durable value over rapid ownership targets. The firm is sector-agnostic and prioritizes people and execution, partnering with exceptional founders from idea to IPO. Its portfolio includes notable companies such as Uber, SeatGeek, WHOOP, Shield AI, The Trade Desk, and Suno. The team combines hands-on partnership with an extensive network to support portfolio companies throughout growth and scale.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Accomplice is a seed- and early-stage venture capital firm based in Cambridge and Boston, Massachusetts, that backs technology startups. It concentrates on cybersecurity, esports, data analytics, SMB-class software, emerging hardware platforms, and marketplaces, and pursues a community-minded approach through platforms such as AngelList, Boston Syndicates, Maiden Lane, Spearhead, BOSS, Rev, and TUGG to support founders. While most investments target Boston and New England, Accomplice also backs companies across the United States, Canada, and Europe, reflecting its role as an active, hands-on investor in early-stage technology ventures.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Spark Capital is a venture capital firm founded in 2005 with offices in San Francisco, Boston, and New York. It invests in early-stage and growth companies across a wide range of sectors, including consumer, software, media, fintech, education technology, and internet services, supporting founders who pursue ambitious ideas and seek product-led strategies. The firm is known for backing prominent companies such as Twitter, Discord, Oculus, Warby Parker, Tumblr, Niantic, and others, reflecting a willingness to back disruptive teams and markets. Spark Capital emphasizes a founder-centric approach, prioritizing listening, product-market fit, independence of thought, and resilience, and aims to help portfolio companies scale on their own terms. By partnering across stages and geographies, the firm seeks to build enduring, value-driving businesses in the United States and beyond.

Third Rock Ventures is a Boston-based venture capital firm focused on early-stage life sciences and healthcare companies. Founded in 2007, it targets companies developing therapies, diagnostics, devices, and related technologies that address unmet medical needs. The firm seeks meaningful, high-growth opportunities in the United States, often leading initial investments and engaging actively in portfolio companies, sometimes taking management roles or forming strategic collaborations with larger pharmaceutical and biotechnology partners. Third Rock emphasizes hands-on involvement and strategic support to accelerate product development and market progress, with a history of funding companies across oncology, cardiovascular, immunology, gene therapy, and other therapeutic areas. The firm operates through multiple venture funds and maintains a focus on Boston, with additional presence in San Francisco, and aims to foster patient-centric, transformative medicines and technologies.

Deerfield Management is a New York City-based healthcare investment and information platform that advances healthcare through flexible funding models, AI-driven intelligence, and philanthropy. It connects people, capital, ideas, and technology across the healthcare ecosystem by investing in and building companies, powered by Deerfield Discovery and Development (3DC), a company-building R&D engine where bench scientists and industry veterans collaborate, and Cure, a New York City hub housing portfolio companies and in-building labs with advanced equipment. It has partnered with Blue Cross Blue Shield of North Carolina to build Alo, a platform enabling independent physicians to manage the business of medicine. Its Intelligence offering leverages AI, data, and market research to drive healthcare technology and innovation, while the Deerfield Foundation funds philanthropic initiatives in education, healthcare access, and health outcomes. The firm pursues strategic partnerships and external collaborations to accelerate progress across biotechnology, pharmaceuticals, diagnostics, devices, and services.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

Hyperplane Venture Capital is a Boston-based early-stage venture capital firm that invests in technology companies, particularly those applying artificial intelligence, machine learning, data-centric approaches, cloud computing, automation, and related fields. The firm backs exceptional founders and supports portfolio companies through multiple funding rounds, often providing early checks and ongoing guidance as they scale. Hyperplane emphasizes building solutions at the nexus of perception, communication, intelligence, and insight, and seeks opportunities where AI and related technologies can transform industries.

Based in Boston, Massachusetts, .406 Ventures is an early-stage venture capital firm that backs B2B technology companies in the Northeast United States. It focuses on information technology and services, cybersecurity, cloud and data infrastructure, next-generation software, AI, fintech, digital health, and technology-enabled business services. The firm typically acts as lead or first institutional investor in de novo and early-stage rounds, reserves capital for follow-ons, and provides strategic guidance through domain expertise and networks to help founders scale. Initial investments usually range in the low to mid single millions, with total commitments up to about $10 million per company. The approach emphasizes long-term partnerships with entrepreneurs to build market-leading companies.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates on life sciences, digital health and health tech, and related technologies, including diagnostics, therapeutics, artificial intelligence and machine learning. It seeks to back companies translating scientific advances into practical solutions with significant societal impact, combining rigorous scientific assessment with strategic partnerships to support research, development and commercialization.

MPM Capital is a Cambridge-headquartered healthcare investment firm that funds biotechnology, oncology, and life sciences companies. It invests across the company lifecycle, from seed and early development to growth and late-stage programs, aiming to translate scientific advances into clinical outcomes. The firm backs ventures in medical technology, oncology, specialty pharma, and medical devices and pursues global opportunities in the United States, Europe, and Asia, with a focus on India. Founded in 1996, MPM Capital collaborates with researchers, clinicians, and entrepreneurs to support portfolio companies through development milestones and proof-of-concept data.

Pillar VC is an early-stage venture capital firm based in Boston, founded in 2016 by a group of CEOs who have built successful companies. The firm concentrates on technically driven startups, particularly in AI, biotech, and healthcare, and partners with founders from inception to help turn ideas into scalable businesses. Pillar VC emphasizes hands-on support, offering resources such as pitch deck templates, financial models, and investor outreach guidance to assist portfolio companies in navigating early-stage growth. Notable portfolio companies include Neural Magic, Abridge, PathAI, and Latent Labs. Pillar VC seeks to back breakthroughs that can redefine industries and improve patient outcomes.

LaunchPad Venture Group is an angel investment group and venture capital firm based in Boston, Massachusetts, serving New England. Founded in 2001, it focuses on early-stage science and technology startups, providing both financial capital and strategic guidance. The firm emphasizes long-term relationships with founders and offers mentorship, drawing on a network of customers, service providers, partners, and potential subsequent financing. Its portfolio spans software, information technology, web and mobile applications, e-commerce, media and social platforms, healthcare IT, medical devices and diagnostics, networking and telecom, and clean-tech and renewable energy. The organization has invested more than 125 million in more than 150 companies, underscoring its hands-on approach to helping entrepreneurs scale.

Safar Partners is a Cambridge, Massachusetts-based venture capital firm founded in 2018 that backs seed- to growth-stage technology startups. The firm sources opportunities from the research ecosystem at MIT, Harvard, and the University of Rochester and focuses on platform technologies in cleantech and advanced materials, AI/IT and robotics, and life sciences and medical devices. Safar Partners leverages university connections and an advisory network to support portfolio companies through their lifecycle while integrating ESG considerations into its investment decisions. The firm aims to generate strong returns by funding early-stage ventures with the potential to scale technologically and commercially within the United States.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

Beacon Angels is a Boston-based angel investment group founded in 2006 that backs early-stage and fast-growing companies in New England. The group targets investments typically ranging from $50,000 to $400,000, providing capital and support to entrepreneurs. Membership is limited to accredited investors who participate in a structured process with monthly meetings to review presentations and conduct deal screening. Beacon Angels coordinates deal flow through the Gust platform to connect members with investment opportunities and foster collaboration within the regional startup ecosystem.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

CRV, founded in 1970 as Charles River Ventures, is a Palo Alto and Cambridge-based venture capital firm focused on seed to Series B technology, consumer, and healthcare companies in North America. The firm takes a hands-on, value-added approach, partnering with founders beyond capital to guide product, strategy and growth through the early stages and beyond. With offices in Cambridge, MA and Menlo Park, CA, CRV supports portfolio companies from initial concept to scale, and has backed notable startups such as DoorDash, Mercury and Vercel, illustrating a long history as one of the industry’s oldest venture firms.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

E14 Fund is a Cambridge, Massachusetts-based venture capital firm that backs early-stage technology startups, primarily at seed and pre-Series A stages. The firm focuses on technologies originating from MIT and beyond, including artificial intelligence, robotics, biotechnology, smart cities, consumer electronics, and manufacturing. It provides capital typically in the range of hundreds of thousands to around one million dollars per company and supports portfolio companies through a network of investors, industry experts, and entrepreneurs to help turn prototypes into scalable businesses. E14 Fund emphasizes a community approach, offering resources and connections that aid founders in fundraising and growth, and it highlights diversity and inclusion as a source of innovation with a globally diverse founder base.

Boston Seed Capital is a seed- and early-stage venture capital firm based in Massachusetts, founded circa 2010 with operations in Boston and Wellesley Hills. It backs internet-enabled and technology-driven startups, including consumer products, B2B software-as-a-service, and infrastructure-focused ventures, as well as related areas such as information technology, cybersecurity, e-commerce, big data, AI and machine learning, and marketplaces. The firm concentrates on founder-led companies across the United States, providing early support to help them reach scale.

Refactor is a seed-stage venture firm led by Zal Bilimoria and based in Burlingame, California. It backs US-based hard-tech startups that build physical systems—atoms, not bits—with a founder-first approach and early checks. The firm targets durable moats, long development cycles, and sticky customer value across aerospace, energy, bio, critical materials, immune health, and AI infrastructure. Its portfolio includes Clover Health, Uniform Teeth, Kip, and other ventures that have achieved notable outcomes, including Clover Health’s public listing and Uniform Teeth’s acquisition by Impress and Kip’s acquisition by Modern Health. Refactor originated as an early spinout connected to a16z’s Bio Fund and remains focused on supporting ambitious teams rebuilding industries. Based in Burlingame, the firm invites founders to pitch and emphasizes measurable, durable impact over rapid exits.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.

Fontinalis Partners is a Detroit- and Boston-based venture capital firm focused on next-generation mobility and related technologies. Founded in 2009, it invests across stages in mobility, transportation, software, and services, with emphasis on early-stage to growth opportunities. The firm backs startups addressing connected vehicles, data and analytics, intelligent infrastructure, location-based services, and new mobility models such as car sharing and ride-hailing, and it pursues an intermodal approach across road, rail, air, and maritime domains. Fontinalis acts as a strategic partner, drawing on management experience, market access, and industry relationships to help portfolio companies scale, and it frequently takes board seats. In addition to mobility, it targets software and data-centric tech across the broader transportation ecosystem.

Longwood Fund is a Boston-based venture capital firm that builds and supports science-driven healthcare companies, translating laboratory discoveries into therapies. It partners with scientific co-founders to identify breakthroughs and actively participates in building portfolio companies, sometimes taking leadership roles such as CEO or other executive positions. The firm concentrates on medical and biotechnology ventures, drawing on technologies from premier academic labs and universities, with a focus on accelerating development from lab to patient. Longwood emphasizes collaboration and entrepreneurial expertise, with a track record of involvement in creating and supporting notable biotech ventures and therapies, and a stated orientation toward healthcare, pharmaceuticals and life sciences.

Gutbrain Ventures is an independent Boston-based venture capital firm that invests primarily in enterprise software companies. Founded by Bob Davoli, the firm emphasizes hands-on support, leveraging Davoli’s background as an entrepreneur to provide strategic guidance and operational assistance to portfolio companies, with a focus on long-term value creation in the software industry.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It funds technology startups across seed to late stages, with investments spanning software, cloud infrastructure, enterprise software and services, consumer internet, fintech, artificial intelligence, crypto, infrastructure, and biotechnology at the intersection of computer science and life sciences. The firm emphasizes supporting portfolio companies through growth and strategic partnerships and maintains a broad tech-focused investment approach, aiming to add value beyond capital.

NextView Ventures is a venture capital firm that provides seed and early-stage backing to entrepreneurs across North America. With offices in New York, Boston, and San Francisco, it partners with founders from inception to scale, offering hands-on support and strategic guidance drawn from experience building iconic companies. The firm pursues thematic investments across sectors such as fintech, health, consumer products, software, ecommerce, and B2B, and backs companies positioned to achieve meaningful impact. It has a history of notable investments in WHOOP and Bobbie and provides founders with resources through a founder portal, webinars, and published perspectives. Founded in 2010 and headquartered on the East Coast, NextView emphasizes a collaborative, founder-centric approach, often taking leadership or board roles in its portfolio companies to accelerate growth through practical, operational insight.

EcoR1 Capital is a biotechnology-focused venture capital firm based in San Francisco. The firm seeks to invest in biotech companies and drug discovery programs, aiming to support scientific breakthroughs and develop new medicines. It pursues long-term partnerships with ambitious entrepreneurs and favors a collaborative approach that leverages curiosity and a deep understanding of molecular mechanisms to identify and realize opportunities in biology and chemistry. As a registered investment adviser, EcoR1 Capital positions itself to back innovative therapies addressing unmet medical needs and to contribute to advances that improve patients' lives.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

LaunchCapital is a venture capital firm founded in 2008 and based in New Haven, Connecticut, with offices in Boston, New York, New Haven, and San Francisco. It concentrates on seed and early-stage investments, typically providing initial capital in the range of $50k to $150k and pursuing significant follow-on investments for standout companies. The firm operates two investment vehicles: LaunchCapital Ventures, which provides equity in high-growth opportunities, and LaunchCapital Small Business, blending equity and debt to support near-term revenue and local or regional growth. It backs a broad range of sectors, including technology, commerce, consumer and medical technologies, media and entertainment, enterprise software and services, data, finance, healthcare, and emerging tech. LaunchCapital emphasizes a hands-on, long-term partnership with entrepreneurs and has over 200 portfolio companies across diverse industries, seeking national reach. The group is backed by the Pritzker/Vlock Family Office and targets opportunities nationwide.

Glasswing Ventures is a Boston-based venture capital firm founded in 2016 that concentrates on early-stage investments in artificial intelligence, frontier technologies, and related software for enterprise and cybersecurity markets. The firm backs AI-native solutions and companies developing intelligent enterprise software, contract intelligence, data engineering, and other AI-enabled capabilities. Glasswing engages with portfolio companies through its technical expertise, advisory councils, and a Building Partners model that provides executive-level support. It concentrates on pre-seed to early-stage rounds in North America, with emphasis on the East Coast and Boston and New York areas, and typically writes checks in the range of about $1.5 to $3 million across 15 to 20 companies. Glasswing emphasizes thought leadership and ecosystem-building, publishing content such as the AI Atlas and leveraging partnerships with leaders from major technology companies to foster growth.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Battery Ventures is a global technology investment firm founded in 1983 and based in Boston. It provides growth equity and venture capital to technology companies across sectors including application software, infrastructure software, consumer, industrial technology, and life science tools, investing in early through late stages and supporting buyouts. The firm operates internationally with offices in multiple locations and emphasizes a team-based, thesis-driven approach and close relationships with company leadership. Over its history, Battery Ventures has backed more than 450 companies, reflecting a focus on technology-driven growth and long-term partnerships.

Castor Ventures is an investment firm that builds diversified venture portfolios by investing in a broad range of venture-backed companies and often co-investing alongside established venture firms.